NRX Pharmaceuticals Inc Ordinary Shares NRXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
-
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
-
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
-
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
-
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System
-
NRx Pharmaceuticals to Participate in Upcoming Investor Conferences
-
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET
-
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans
Trading Information
- Previous Close Price
- $2.55
- Day Range
- $2.53–2.71
- 52-Week Range
- $1.62–5.06
- Bid/Ask
- $2.69 / $2.80
- Shares Outstanding
- 43.30M
- Market Cap
- $116.47M
- Volume/Avg
- 546 / 876,033
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 24.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://nrxpharma.com
Valuation
|
Metric
|
NRXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 24.00 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NRXP
|
|---|---|
Quick Ratio | 0.79 |
Current Ratio | 0.86 |
Interest Coverage | −19.59 |
Quick Ratio
NRXP
Profitability
|
Metric
|
NRXP
|
|---|---|
Return on Assets (Normalized) | −92.69% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NRXP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|PW%&^# | LOCK|l>rX@ | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|g!>gKW | LOCK|z?Wg | $84B | |||
| Moderna Inc
MRNA
| LOCK|?!n&&y$ | LOCK|^D | $83B | |||
| argenx SE ADR
ARGX
| LOCK|#bcXWN | LOCK|%p | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Kl@%bF | LOCK|^Lf | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hznD#w | LOCK|^Pz#Q | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|PCxH^T^ | LOCK|>q&$ | $29B | |||
| Incyte Corp
INCY
| LOCK|>Z#h?$& | LOCK|Hs | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|mH^>!m | LOCK|<sG | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?>$>T^! | LOCK|<Zn | $14B |
United States